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Abstract. The aim of the present study is to compare the
safety, efficacy and cost effectiveness of anesthetic regimens
by compound, using etomidate and propofol in elderly patients
undergoing gastroscopy. A total of 200 volunteers (65‑79 years
of age) scheduled for gastroscopy under anesthesia were
randomly divided into the following groups: P, propofol
(1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E, propofol
(0.75‑1 mg/kg) followed by etomidate (0.075‑0.1 mg/kg);
and E+P, etomidate (0.075‑0.01 mg/kg) followed by propofol
(0.75‑1 mg/kg). Vital signs and bispectral index were monitored at different time points. Complications, induction and
examination time, anesthesia duration, and recovery and
discharge time were recorded. At the end of the procedure,
the satisfaction of patients, endoscopists and the anesthetist
were evaluated. The recovery (6.1±1.2 h) and discharge times
(24.8±2.8 h) in group E were significantly longer compared
with groups P, P+E and E+P (P<0.05). The occurrence of
injection pain in group P+E was significantly higher compared
with the other three groups (P<0.05). In addition, the incidence
of myoclonus and post‑operative nausea and vomiting were
significantly higher in group P+E compared with the other
three groups (P<0.05). There was no statistical difference
among the four groups with regards to the patients' immediate,
post‑procedure satisfaction (P>0.05). Furthermore, there was
no difference in the satisfaction of anesthesia, as evaluated
by the anesthetist and endoscopist, among the four groups
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(P>0.05). The present study demonstrates that anesthesia for
gastroscopy in elderly patients can be safely and effectively
accomplished using a drug regimen that combines propofol
with etomidate. The combined use of propofol and etomidate
has unique characteristics which improve hemodynamic
stability, cause minimal respiratory depression and less side
effects, provide rapid return to full activity and result in high
levels of satisfaction.
Introduction
Gastroscopy is a well‑established, highly effective diagnostic
and therapeutic procedure. The frequency of this procedure
in the elderly is increasing rapidly as the general population
ages (1,2). Although it is a non‑traumatic invasive procedure, it often causes significant discomfort in the majority
of patients. With the collaboration of the anesthesia and
digestive system departments, gastroscopy under anesthesia
minimizes the risk of physical injury occurring during
examination, and provides the endoscopist with a suitable
environment for a thorough examination. This has been
reported to be safe in high risk patients, including elderly,
frail and seriously ill patients (3,4). Despite the benefits of
using anesthesia for gastroscopy, it has significant drawbacks. Anesthesia can delay patient recovery and discharge
time, and increases the risk of cardiopulmonary complications, which are understood to account for ~50% mortality
and ~60% morbidity associated with upper gastrointestinal
endoscopy (5,6). This risk is increased in elderly patients or
those with cardiovascular diseases and upper gastrointestinal
bleeding (7). Arterial hypoxemia, arrhythmias and myocardial ischemia have been reported following gastroscopy with
anesthesia (7).
Anesthesia strategies for gastroscopy have been explored
for decades. There are numerous reports on the safety profile
of propofol used for anesthesia during gastrointestinal
endoscopy (8‑10). Propofol is currently the most frequently
used intravenous anesthetic, due to its rapid recovery profile,
and is widely used in outpatient surgeries and examinations (4,10). The most prominent undesirable effect of propofol

1516

MENG et al: ETOMIDATE AND PROPOFOL USE IN ELDERLY GASTROSCOPY

is its marked depression on cardiovascular and respiratory
parameters, particularly in elderly patients (9‑10). The
distinct pharmacological characteristics of etomidate include
improved hemodynamic stability and minimal respiratory
depression (11). This results in a wider margin of safety for
patients with significant risk factors, including patients with
valvular heart disease and myocardial ischemia, and elderly
patients. However, due to side effects, including myoclonus
and post‑operative nausea and vomiting (PONV), etomidate is
rarely used in patients undergoing gastroscopy.
The aim of the present prospective study is to determine
the safety, efficacy, cost effectiveness, side effect profile and
recovery time of a combination of propofol and etomidate,
compared with propofol and etomidate alone, as anesthetic
regimens for gastroscopy.
Materials and methods
Patients and study design. The current study is a double‑blinded,
randomized, parallel‑group study, performed in accordance
with the International Conference on Harmonization Good
Clinical Practice guidelines (8). The study was approved by the
Ethics Committee of Renmin Hospital of Wuhan University
(Wuhan, China), and informed consent was obtained from
all patients. A total of 200 healthy, American Society of
Anesthesiologists grade I‑II patients, consisting of 97 males
and 103 females, aged between 65 and 79 years, who were
scheduled for gastroscopy with anesthesia, were included in the
study. Patients had normal serum chemistry, and normal liver
and renal function test results. No patients were experiencing
cardiac or respiratory disease. Exclusion criteria included the
following: Severe dysfunction of heart; lung, liver, kidney and
adrenal insufficiency; sleep apnea syndrome; gastric retention;
history of an allergic reaction to the study drugs; history of
previous experience with endoscopy; patients receiving analgesics, such as nonsteroidal anti‑inflammatory drugs; patients
administered α‑methyldopa, clonidine or a β‑blocker; patients
with psychiatric, neurological or neuromuscular disorders; or
patients who had used drugs, drank alcohol or smoked tobacco
two weeks prior to the study. Demographic data obtained
included age, weight, gender and primary diagnosis. Propofol
and etomidate doses, administered by bolus and continuous
infusion, were recorded.
Medicine preparation, anesthesia monitoring and gastroscopy
procedure. Drugs used in the study included 200 mg/20 ml
propofol (AstraZeneca, London, UK), 20 mg/10 ml etomidate (Nhwa Pharmaceutical Group, Jiangsu, China) and
100 mg/2 ml fentanyl (Yichang Humanwell Pharmaceutical
Co., Ltd., Yichang, China). Etomidate and propofol were diluted
to 20 ml prior to administration. All dugs were prepared by an
anesthesiologist who was blinded to the study. An investigator,
who was blinded to group assignment, assessed and recorded
all observed parameters.
In accordance with hospital policies regarding procedural
anesthesia, fasting status was confirmed, and a 20‑gauge
peripheral IV catheter was placed in the right forearm
without subcutaneous local anesthesia following the arrival
of patients to the Digestive Endoscopy Center of Renmin
Hospital of Wuhan University. Lactated Ringer's solution

(Baxter International Inc., Deerfield, IL, USA) was infused,
and routine monitoring consisting of a 5‑lead electrocardiography (ECG), non‑invasive blood pressure, pulse oxygen
saturation (SpO2) and bispectral index (BIS; Monitor Model
A‑2000; Aspect Medical Systems, Inc., Norwood, MA, USA).
The mean of the final 3 vital signs obtained prior to the injection of anesthetics was recorded as the baseline in all patients.
After lying on the examination table in the left lateral position, each patient was provided oxygen (5 l/min) via a face
mask and instructed to take deep breathes to increase their
oxygen reserves.
All patients received intravenous (i.v.) 1 µg/kg fentanyl
at 5‑10 sec prior to gastroscopy. Prior to endoscopy,
patients were randomized to one of four groups using a
computer‑generated random numbers table, which allocated
50 patients to each group. Patients in the propofol group (P)
received i.v. propofol at an induction dose of 1.5‑2.0 mg.
kg‑1 over a 1 min period using a computer controlled infusion pump (Syringe Infusion Pump Model compact; B.
Braun Melsungen AG, Melsungen, Germany), followed by a
maintenance infusion of 4 mg.kg‑1.h‑1 during the gastroscopy
procedure. Patients in the etomidate group (E) received i.v.
etomidate at an induction dose of 0.15‑0.2 mg/kg over 1 min
using the same infusion pump, followed by a maintenance
infusion of 0.4 µg.kg‑1.h‑1 during the gastroscopy procedure.
Patients in the propofol and etomidate group (P+E) received
propofol (0.75‑1 mg/kg) over a 30 sec period and subsequently etomidate (0.075‑0.1 mg/kg) over a 30 sec period
using the same infusion pump, followed by a maintenance
infusion of 2 mg.kg‑1.h‑1 propofol and 0.2 µg.kg‑1.h‑1 etomidate simultaneously during the gastroscopy procedure via
a three‑way joint. Patients in the etomidate and propofol
group (E+P) received etomidate (0.075‑0.01 mg/kg) over
a 30‑sec period and subsequently propofol (0.75‑1 mg/kg)
over a 30 sec period via the same infusion pump, followed
by a maintenance infusion of 2 mg.kg‑1.h ‑1 propofol and
0.2 µg.kg‑1.h‑1 etomidate during the gastroscopy procedure
via a three‑way joint.
Gastroscopy was performed when eyelash reflexes disappeared. The gastroscopy was performed with patients in a
left lateral position, using a side‑viewing video duodenoscope
(Olympus Optical Co., Ltd., Tokyo, Japan). An anesthetist was
in attendance during all procedures. Spontaneous respiration
was maintained during the course of gastroscopy.
Observed parameters. A 5‑lead ECG was performed
throughout the gastroscopy. In addition, reductions in SpO2,
changes in heart rate (HR) and blood pressure (BP), ST
segment deviations, arrhythmias and conduction defects were
recorded throughout the procedure. Vital signs were recorded
at T0 (baseline, prior to induction of anesthesia), T1 (2 min
after induction of anesthesia), T2 (4 min after induction of
anesthesia), T3 (6 min after induction of anesthesia), T4 (8 min
after induction of anesthesia), T5 (10 min after induction of
anesthesia), T6 (15 min after induction of anesthesia) and T7
(20 min after induction of anesthesia).
Patients were assessed at the following time points
for various complications: i) Start of anesthesia (first
drug bolus); ii) start of examination (gastroscopy placement); iii) completion of the examination (removal of the
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gastroscopy); iv) 'induction time' (start of anesthesia to start
of examination); v) 'inspection time' (gastroscopy insertion to
gastroscopy removal); vi) 'recovery time' (the time between
the gastroscopy removal and the start of the final psychometric assessment); and vii) 'discharge time' (the time between
gastroscopy removal and departure from the endoscopy unit).
The criteria for discharge from the endoscopy unit were as
follows: Fully awake with stable hemodynamics; no evidence
of respiratory depression; no nausea or vomiting; and ability
to drink water safely.
Rate pressure product (RPP) and pressure‑rate quotient
(PRQ) (12), which are two indices that reflect myocardial
oxygen consumption, were calculated following the examination as follows: RPP = systolic blood pressure (SBP) x heart
rate (HR) / 1,000; PRQ = mean arterial pressure / HR.
Adverse events, the use of ventilator support, including
support of the oral or nasopharyngeal airways, and the administration of pressors and chronotropic agents were recorded.
Bradycardia was defined as a heart rate <50 beats per minute
(bpm). Hypotension was defined as a systolic pressure <70%
baseline or <80 mmHg. Side effects, including PONV, swallowing, body movement (limb locomotor activity with no
influence on gastroscopy), serious body movements (resulting
in suspension of the examination), apnea (interval time of
respiration, >30 sec), hypoxemia (SpO2,<90%), myoclonus
(involuntary and brief twitching of a group of muscles) and
injection pain, were recorded.
At the end of the procedure, the satisfaction of the anesthetist and gastroenterologist were evaluated according to the
visual analogue scale (13) (VAS scores; 0 = no satisfaction
and 10 = most satisfaction). A questionnaire, which inquired
about i) overall satisfaction with the anesthesia, ii) difficulty of
anesthesia, iii) patient cooperation, and iv) overall satisfaction
with the gastroscopy procedure, was used.
Prior to discharge, patient satisfaction was evaluated by
completing an anonymous and confidential Patient Satisfaction
Questionnaire, modified from Sipe (14), to evaluate the endoscopy experience.
Safety equipment. Vital signs were monitored for 2 h after the
completion of the examination. The incidence of the following
cardiorespiratory events were recorded: Bradycardia; respiratory depression (RR; <9 breaths/min); apnea; hypertension
(BP >30% baseline); and hypotension (BP <30% baseline).
Intervention, including the administration of fluid, pressors,
or the use of an anticholinergic agents, was applied for any
adverse events. Mask‑assisted ventilation was performed if
SpO2 <90% remained for 30 sec. Additionally, any events
resulting in mortality, permanent impairment, hospitalization and/or medical or surgical intervention were recorded.
Statistical analysis. Data are presented as the mean ± standard deviation, and medians. GraphPad Prism version 5.0
(GraphPad Software, Inc., San Diego, CA, USA) was used
to analyze the results. One‑way analysis of variance was
performed to examine differences among the four groups with
respect to parametric variables, followed by Tukey's post hoc
test. Incidences of complications were analyzed using the χ2 or
Fisher's exact test. P<0.05 was considered to indicate a statistically significant difference.
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Results
Combined use of propofol and etomidate reduces recovery
and discharge times, as compared with etomidate alone.
A total of 253 patients were assessed for study eligibility;
35 patients did not meet the inclusion criteria, 15 patients
declined to participate and 3 patients were excluded for other
reasons (Fig. 1). In total, 200 patients were included in the
study (97 males and 103 females; age range, 65‑82 years). The
four groups had similar demographic data (P>0.05; Table I)
and BIS (P>0.05; Table I). The induction time, inspection
time and anesthesia duration were not different between the
four groups (P>0.05; Fig. 2). The recovery (6.1±1.2 h) and
discharge times (24.8±2.8 h) in group E were longer compared
with group P (4.8±0.9 h and 22.7±2.8 h, respectively), group
P+E (5.2±0.9 h and 23.6±1.4 h, respectively) and group E+P
(5.3±0.8 h and 23.5±1.8 h, respectively) (P<0.05; Fig. 2). No
gastroscopy procedure was terminated because of inadequate
patient anesthesia.
Etomidate improves hemodynamic stability, as compared
with propofol. A decrease in BP >30% from the baseline
occurred in 62 patients across all groups (Table II). There was
a decrease in SBP from the baseline in all patients at T1, and
there was a significant difference in the incidence of hypotension in group P, as compared with the other three groups (88%;
P<0.05; Fig. 3). In addition, there were statistically significant
differences in SBP in group P at T1, as compared with the
other three groups (P<0.05; Fig. 3), and there were significant
differences in SBP at T0 compared with T1, T2, T3, T4, T5 and
T6 in group P (P<0.05; Fig. 3). Furthermore, there was a significant difference in SBP at T0 compared with T1, T2, T3, T4
and T5 in groups E, P+E and E+P (P<0.05; Fig. 3). Moreover,
in groups E, P+E and E+P, there was a significant difference in
SBP at T1 (132.08±6.56, 129.56±6.58 and 131.20±5.93 mmHg,
respectively) compared with T6 (151.28±5.73, 150.72±5.79
and 152.16±6.65 mmHg, respectively) and T7 (157.44±5.36,
154.36±8.04 and 158.68±5.71 mmHg, respectively) (P<0.05;
Fig. 3). The results for the other three groups showed improved
hemodynamic stability compared with group P (P<0.05,
Fig. 3). There were no significant differences in the mean and
maximum HR during gastroscopy in different groups (P>0.05,
Fig. 3). It has been suggested that RPP ≥12 indicates myocardial ischemia (12), and that RPP ≥20 is a threshold for angina
pectoris; PRQ <1.0 is considered to be an accurate measure of
myocardial ischemia. In the present study, 1 patient had a very
high RPP (>20), and 2 patients had PRQ <1.0, in group P.
Combined use of propofol and etomidate causes minimal
respiratory depression and few side effects. The incidences
of complications resulting from gastroscopy are presented
in Table II. No serious complication occurred during the
study. Transient hypoxia (SpO2, <90% for >30 sec) requiring
supplemental oxygen by mask‑assisted ventilation occurred in
7 patients across all groups (Table II). All episodes of hypotension and bradycardia were transient, and the administration of
a pharmacologic agent or other therapeutic intervention was
not required to treat any of the patients. No perforations or
mortality occurred, and following the procedure, no patient
required assisted ventilation or was admitted to hospital.
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Table I. Patient demographics.
Group
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Parameter
P
E
P+E
E+P
Median age (range), years
Gender, male/female
Median weight (range), kg

68.4 (65‑78)
24/26
60.7 (50‑84)

69.7 (65‑80)
25/25
62.4 (52‑82)

72.3 (65‑79)
24/26
62.6 (47‑85)

71.8 (65‑82)
24/26
61.8 (49‑84)

There are no significant difference between the treatment groups (P>0.05). P, propofol (1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E,
propofol (0.75‑1 mg/kg) followed by etomidate (0.075‑0.1 mg/kg); E+P, etomidate (0.075‑0.01 mg/kg) followed by propofol (0.75‑1 mg/kg).

Figure 1. Study profile. Flow diagram of the phases of the randomized trial.

The occurrence of apnea during and following gastroscopy
was 17% (34); 2% of these patients had SpO2 <90%, and 2.5%
of the patients reported accessing mask‑assisted ventilation
in the endoscopy unit. The occurrence of SpO2 <95% (24%),
SpO2 <90% (8%), apnea (42%) and mask‑assisted ventilation

(8%) in group P were significant higher compared with groups
E (4, 0, 14 and 2%, respectively), P+E (6, 0, 6 and 2%,
respectively) and E+P (6, 0, 6 and 2%, respectively) (P<0.05;
Table II). There were no significant differences in the occurrence of SpO2 <95%, SpO2 <90%, apnea, and mask‑assisted
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Figure 2. (A) Induction time, (B) inspection time, (C) anesthesia duration, (D) recovery time and (E) discharge time of the four study groups (n=50). Data are
presented as the mean ± standard deviation. *P<0.05. P, propofol (1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E, propofol (0.75‑1 mg/kg) followed by
etomidate (0.075‑0.1 mg/kg); E+P, etomidate (0.075‑0.01 mg/kg) followed by propofol (0.75‑1 mg/kg).

ventilation when comparing groups E, P+E and E+P (P>0.05;
Table II).
ECG changes during and following gastroscopy occurred
in 22.5% of all procedures. In group P, related transient ECG
changes included ST segment depression (20%), transient
atrial fibrillation (4%), sinus bradycardia (10%) and ventricular premature complexes (2%). In group E, sinus bradycardia
occurred in 12% of procedures and ST segment changes
occurred in 6% of patients. In group P+E, the occurrence
of bradycardia was 10%, and ST segment changes occurred
in 8% of patients. In the E+P group, sinus bradycardia
occurred in 8% and ST changes occurred in 6% of patients.
The difference in the incidence of arrhythmia and ischemic
changes between the four groups was not significant (P>0.05;
Table II).
The occurrence of myoclonus during and following
gastroscopy with anesthesia in group E (30%) was significantly higher compared with groups P (2%), P+E (4%) and

E+P (6%) (P<0.05). The occurrence of injection pain during
and following gastroscopy in group P (64%) was significantly
higher compared with groups E (6%), P+E (20%) and E+P (6%)
(P<0.05). The occurrence of injection pain in group P+E was
significant higher compared with groups E and E+P (P<0.05).
There were no statistical differences between groups P and E
with regards to the occurrence of body movements (P>0.05;
Table II). One patient moved significantly enough to require
suspension of the gastroscopy while additional propofol
was given. The occurrence of body movements significantly
decreased using propofol and etomidate together, regardless
of which drug was administered first (P<0.05; Table II). Body
movements occurred in 42 patients (21%), the majority of
which were general body movements (97.6%). The incidence
of PONV in group E (14%) was significantly higher compared
with group P (8%) (P<0.05; Table II). There was no statistical
difference in the incidence of PONV between groups P, P+E
and E+P.
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Figure 3. Mean (A) SBP, (B) DBP and (C) HR levels of the four study groups (n=50) during gastroscopy. Data are presented as the mean ± standard deviation.
There was a significant difference between SBP in group P at T1 compared with T0 (P<0.05), and there were significant differences in SBP at T0 compared
with SBP at T1, T2, T3, T4, T5 and T6 in group P (P<0.05). In addition, there were significant differences in SBP at T0 compared with T1, T2, T3, T4 and
T5 in groups E, P+E and E+P (P<0.05). Furthermore, there were significant differences in SBP at T1 compared with T6 and T7 in groups E, P+E and E+P
(P<0.05). However, there were no significant differences in HR in any groups (P>0.05). SBP, systolic blood pressure; DBP, diastolic blood pressure; HR,
heart rate; P, propofol (1.5‑2.0 mg/kg); E, etomidate (0.15‑0.2 mg/kg); P+E, propofol (0.75‑1 mg/kg) followed by etomidate (0.075‑0.1 mg/kg); E+P, etomidate
(0.075‑0.01 mg/kg) followed by propofol (0.75‑1 mg/kg).

Combination of propofol and etomidate increases patient
satisfaction following a gastroscopy, as compared with using
either agent alone. Patient evaluation of the gastroscopy is
presented in Table III. The immediate post‑procedure questionnaire was completed by all patients. In group P, 90% of
patients described their overall satisfaction with the anesthesia as ̔excellent̓ and 10% rated it ̔good̓ when asked to
rate the degree of pain or discomfort experienced during the
endoscopy. Meanwhile, in group E, 80% of patients described
overall satisfaction as ̔excellent̓, 12% described it as ̔good̓
and 8% of patients described it as ̔fair̓. In the P+E and E+P
groups, overall satisfaction was rated as excellent in 90 and
92% of patients, respectively, which is significantly increased
compared with groups P and E (P>0.05; Table III).
In group P, 80% of patients reported no discomfort, 16%
described discomfort as mild, and 4% described discomfort
as moderate; 90% of patients rated the level of anesthesia as
̔adequate̓, 8% believed that they received ̔too little̓, and 2%
stated that they were given ̔too much̓. In group E, 72% of
patients reported no discomfort, 24% described discomfort
as mild and 4% described discomfort as moderate; 92%
of patients rated the level of anesthesia as ̔adequate̓, 6%
believed that they received ̔too little̓ and 2% stated that they
were given ̔too much̓. In groups P+E and E+P, 80 and 78%

reported no discomfort, respectively, 18 and 20% described
discomfort as mild, respectively, and 2% in both groups
described discomfort as moderate. All patients rated the level
of anesthesia as ̔adequate̓ when asked to rate the level of
anesthesia during the endoscopy following co‑administration
of propofol and etomidate (P>0.05; Table III).
Combination of propofol and etomidate provides Although
the survey was conducted 24 h after discharge, it was shown
that different proportions of patients in the four groups returned
to normal activities within 2 h of discharge. Group P patients
required ≥4 h before resumption of activities, although the
majority of patients did not require additional sleep following
discharge from the endoscopy unit. There were no statistical
differences between group P and the other three groups
with regard to the patients' immediate and post‑procedure
satisfaction (P>0.05; Table III). Finally, in the present study,
a combination of propofol and etomidate provided better
satisfaction of endoscopists (P<0.05) and anesthetists (P<0.01)
compared with using propofol alone (Fig. 4).
Discussion
The results of the present study demonstrate that there is
improved hemodynamic stability and minimal respiratory
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Table II. Complications of the four study groups (n=50).
Group
	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Parameter
P
E
P+E
E+P
Hypotension
ST segment depression
Transient atrial fibrillation
Sinus bradycardia
Ventricular premature complexes
SpO2 <95%
SpO2 <90%
Apnea
Mask assisted ventilation
Body movements
Body movements, general
Body movements, serious
Myoclonus
Injection pain
PONV

44 (88)
10 (20)
2 (4)
5 (10)
1 (2)
12 (24)
4 (8)
21 (42)
4 (8)
13 (26)
12 (24)
1 (2)
1 (2)
32 (64)
4 (8)

6 (12)a
3 (6)a
0 (0)
6 (12)
0 (0)
2 (4)a
0 (0)a
7 (14)a
1 (2)a
18 (36)
18 (36)
0 (0)
15 (30)a
3 (6)a
7 (14)a

6 (12)a
4 (8)a
0 (0)
5 (10)
0 (0)
3 (6)a
0 (0)a
3 (6)a
1 (2)a
5 (10)b
5 (10)
0 (0)
2 (4)
10 (20)a,b
5 (10)

6 (12)a
3 (6)a
1 (2)
4 (8)
1 (2)
3 (6)a
0 (0)a
3 (6)a
1 (2)a
6 (12)b
6 (12)
0 (0)
3 (6)
3 (6)a
6 (12)

Data are n (%). aP<0.05, vs. group P, bP<0.05, vs. group E. SpO2, pulse oxygen saturation; PONV, post‑operative nausea and vomiting.

A

B

Figure 4. VAS score of (A) endoscopists and (B) anaesthetists of the four
study groups (n=50). Data are presented as the mean ± standard deviation.
*
P<0.05, vs. group P; VAS, visual analogue scale; P, propofol (1.5‑2.0 mg/kg);
E, etomidate (0.15‑0.2 mg/kg); P+E, propofol (0.75‑1 mg/kg) followed by
etomidate (0.075‑0.1 mg/kg); E+P, etomidate (0.075‑0.01 mg/kg) followed
by propofol (0.75‑1 mg/kg).

depression in elderly patients when propofol is used in combination with etomidate, instead of either agent used alone, for
anesthesia during gastroscopy. Co‑administration of propofol

and etomidate has a favorable side effect profile, allows rapid
recovery to full activity and provides high levels of satisfaction.
Gastroscopy is a non‑traumatic invasive procedure used for
the diagnosis of gastrointestinal pathology and for treatment for
gastrointestinal hemorrhage, polypus and corpus alienum (3).
Elderly patients experience specific physiological changes of
organs and cell functions (15,16), and it is important to understand how to maintain hemodynamic stability and adequate
spontaneous respiration during gastroscopy procedures in
such patients. Gastroscopy is frequently performed with anesthesia for the comfort of the patient. Elderly patients requiring
gastroscopy frequently have cardiovascular disease and other
co‑morbidities, which results in difficulties in safely administering anesthesia while maintaining stable hemodynamics. The
features of gastroscopy examination require that the anesthetic
regimen provides rapid induction, sufficient anesthesia, hemodynamic stability, quick recovery and minimal side effects.
Propofol is the most frequently used i.v. anesthetic to
date due to its rapid recovery profile, and it has been widely
used for anesthesia in outpatients (8,9). However, propofol
causes marked depression on hemodynamic and respiratory
parameters. Hypotension is a common side effect associated
with propofol due to vasodilatation and negative inotropic
effects (11). An induction dose of propofol results in a 25‑30%
incidence of apnea and a 25‑40% reduction in systolic blood
pressure (9,10). The high incidence of apnea, lasting longer than
30 sec, exposes patients to the potential risks of brain damage,
which is the leading cause of morbidity in anesthesia‑related
events (17). In the present study, elderly patients induced with
propofol experienced a 42% incidence of apnea, and 88% of
patients experienced a significant (>30%) reduction in systolic
blood pressure. This may be related to diminished myocardial
contractility, decreased cardiac output, reduced ability of the
cardiovascular system to respond to stress and preoperative
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Table III. Patient satisfaction surveys of four study groups (n=50).
Question and response (n=50)

P

E

P+E

How much discomfort or				
pain did you feel?				
None
40 (80)
36 (72)
40 (80)
Mild
8 (16)
12 (24)
9 (18)
Moderate
2 (4)
2 (4)
1 (2)
Severe
0
0
0
Rate the level of sedation received				
during the endoscopic exam				
Adequate
45 (90)
46 (92)
50 (100)
Too little
4 (8)
3 (6)
0
Too much
1 (2)
1 (2)
0
Rate your overall satisfaction with				
the endoscopic sedation				
Excellent
45 (90)
40 (80)
45 (90)
Good
5 (10)
6 (12)
4 (8)
Fair
0
4 (8)
1 (2)
Poor
0
0
0
Did you require additional sleep during				
the day after your procedure?				
Yes
14 (28)
16 (32)
12 (24)
No
36 (72)
34 (68)
38 (76)
How much sleep did you require?				
None
36 (72)
34 (68)
38 (76)
<2 h
9 (18)
11 (22)
9 (18)
2‑4 h
4 (8)
4 (8)
3 (8)
4‑6 h
1 (2)
1 (2)
0 (0)
When did you resume your normal daily				
activities?				
<2 h
35 (70)
36 (72)
40 (80)
2‑4 h
9 (18)
8 (16)
5 (10)
4‑6 h
3 (6)
3 (6)
2 (4)
>6 h
3 (6)
2 (4)
3 (6)

E+P

39 (78)
10 (20)
1 (2)
0
50 (100)
0
0
46 (92)
3 (6)
1 (2)
0
11 (22)
39 (78)
39 (78)
8 (18)
3 (8)
0 (0)
41 (82)
4 (8)
2 (4)
3 (6)

Data are n (%). In the P+E and E+P groups, overall satisfaction was rated as excellent in 90 and 92% of patients, respectively; this is significantly higher compared with groups P and E (P>0.05).

routine fasting. In contrast, etomidate is associated with
hemodynamic stability and minimal respiratory depression,
which are unique characteristics among rapid‑onset induction
agents (11,18). These properties differentiate etomidate from
other rapid‑onset induction agents, as it has a wider margin
of safety than propofol, particularly in patients with valvular
heart disease, myocardial ischemia and elderly patients. The
results in the current study demonstrated that there was a
14% incidence of apnea and a 12% incidence of hypotension
following the use of etomidate. It is important to note that
there is a significantly decrease in the incidence of apnea (6%),
and a 12% incidence of hypotension, when using propofol and
etomidate together.
Cardiopulmonary complications in elderly patients
have been evaluated during gastroscopy. Elderly patients

who undergo gastroscopy may be at risk of developing
cardiopulmonary complications resulting from preexisting
cardiovascular diseases, the sympathetic response when the
gastroscope is inserted through the throat, and prolonged
procedure time (5,6,19,20). In addition, elderly patients may
be more susceptible to silent myocardial ischemia. The high
incidence of ST segment depression in group P (20%) in the
present study may be related to the reduction in blood pressure resulting from an induction dose of propofol. Although
1 patient developed a very high RPP (>20), and 2 patients
experienced PRQ <1.0, it is not sufficient to conclude that
standard‑dose propofol monotherapy exposes patients to a
high risk of myocardial ischemia. In the current study, there
were no differences in the incidence of transient atrial fibrillation, sinus bradycardia and ventricular premature complexes,
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which indicate that temporary short periods of fluctuations
in blood pressure have little effect on the cardiac conduction
system. Propofol is a potent hypnotic agent that can cause
life‑threatening side effects, including the loss of protective
airway reflexes and respiratory depression (17,21). In the
present study, it was observed that 8% of elderly patients in
group P required short‑term positive pressure ventilation,
while 2% of elderly patients in the other three groups required
this intervention. This result demonstrates that etomidate has
unique characteristics which allow it to be used alone or in
combination with propofol for anesthesia. In addition, the
results show that a combination of etomidate and propofol can
result in favorable hemodynamic stability and preserve spontaneous respirations during anesthesia for gastroscopy.
Etomidate has rarely been used in outpatient operations and during examination due to side effects, such as
myoclonus and PONV. Etomidate has been observed to be
associated with a high (30‑40%) incidence of PONV, and the
incidence of myoclonus following etomidate use is highly
variable (0‑70%) (22,23), which is higher than propofol (22).
In the present study, the incidence of myoclonus, PONV and
injection pain when etomidate combined with propofol was
used and injected in different sequences, was investigated.
The results demonstrate that the incidences of PONV and
myoclonus in group E (14 and 30%, respectively) are higher
compared with group P (8 and 2%), and are reduced by
combined use with propofol (10 and 12% PONV in groups
P+E and E+P, respectively; 4 and 6% myoclonus in groups
P+E and E+P, respectively). In addition, the current study
observed a decreased incidence of injection pain following
the combined use of propofol and etomidate. All of the results
demonstrate that the combined use of propofol and etomidate
results in reducedside effects, including myoclonus, injection
pain and PONV, in elderly patients undergoing gastroscopy.
Furthermore, the present study demonstrated that the combined
use of propofol and etomidate for endoscopic anesthesia, alone
or in combination, results in high levels of patient satisfaction.
In the present study, it was anticipated that a short recovery
time would be accompanied by a rapid recovery to full
activity. In telephone surveys conducted 24 h after discharge
in the current study, it was reported that 72% of patients did
not require additional sleep following discharge, and that 70%
resumed normal activities within 2 h of departure from the
endoscopy unit when propofol monotherapy was used, which
is in agreement with the other results (8). The novel finding
of the present study revealed that 76 and 78% of patients in
groups P+E and E+P, respectively, did not require additional
sleep following discharge, and that 80 and 82% of patients
in groups P+E and E+P, respectively, resumed normal activities within 2 h of departure from the endoscopy unit. This
demonstrates that the combined use of propofol and etomidate
can result in a rapid return to full activity for elderly patients
following gastroscopy.
The present study is subject to a number of limitations.
Firstly, the current study is not a multi‑center study; further
research should be conducted at multiple sites. Although the
study supports the hypothesis that the combined use of etomidate
and propofol reduces the side effects of etomidate and propofol
with minimal effects on safety and recovery, a larger trial that
is sufficient to detect differences is needed to confirm these
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findings before a change in clinical practice is recommended.
Secondly, although plasma corticosteroid concentrations
were not recorded in the current study, a number of studies
have demonstrated that the induction dose of etomidate can
decrease plasma corticosteroid concentrations, and that this
can be sustained for 6‑8 h, leading to adrenocortical dysfunction (24‑26). Thirdly, only the short‑term hemodynamic effects
on elderly patients were investigated. Although no significant
difference was identified in the mortality and hospitalization
among patients who received propofol or etomidate, it can not
determine whether there is any effect on mortality or other
aspects of clinical outcome.
In conclusion, the present study demonstrates that anesthesia for gastroscopy in elderly patients can be safely and
effectively accomplished when propofol combined with etomidate is used. It is understood that these anesthetic regimens
have unique characteristics, including improved hemodynamic
stability, minimal respiratory depression, reduced side effects,
a rapid return to full activity and high levels of satisfaction.
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